CONTEXT AND OBJECTIVE: Breast cancer accounts for approximately one quarter of all cancers in females. Estrogen and progesterone receptor testing has become an essential part of the clinical evaluation of breast carcinoma patients, and accurate results are critical in identifying patients who may benefit from hormone therapy. The present study had the aim of investigating the concordance of the results from hormone receptor tests between a reference laboratory and local (or community) laboratories in Brazil. DESIGN AND SETTING: Retrospective study at a reference pathology laboratory.
INTRODUCTION
Breast cancer is one of the most common human neoplasms, accounting for one quarter of all cancers in females. 1 Hormone therapy is frequently used in breast carcinoma treatment because it reduces the relative risk of recurrence by more than 50% in patients with hormone-sensitive tumors, thus leading to significant improvements in survival. For these reasons, determination of estrogen receptor (ER) and progesterone receptor (PgR) status has become an essential part of the clinical evaluation of all breast carcinoma patients, and accurate results are critical in identifying patients who may benefit from hormone therapy. [2] [3] [4] [5] [6] [7] [8] Immunohistochemistry (IHC) is currently the most common method used for determining ER and PgR status. Low cost and applicability to routinely processed and archived tissue samples are the main advantages of IHC. However, discordances in ER and PgR testing have been reported in the literature, and they have been mostly correlated with technical issues, including fixative and fixation issues, immunohistochemical methodology and diversity of interpretation of results.
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OBJECTIVE
Considering that the accuracy of ER and PgR testing in breast carcinoma is extremely important in selecting the hormone therapy, the present study had the aim of investigating the concordance of the results from ER and PgR tests using IHC between a reference laboratory (Pathology Consultancy, Botucatu, São Paulo, Brazil) and local (or community) laboratories in Brazil.
METHODS
Institutional certifications
This study was approved by the Scientific Committee of the These local laboratories consisted of community-based laboratories with low volumes of ER and PgR testing. The cases included in the study were sent to the reference laboratory by oncologists for confirmation of breast cancer diagnosis and for ER and PgR retesting.
All the cases were morphologically reviewed in the reference laboratory by at least two different pathologists in order to con- 
Statistical analysis
The reference and local laboratories results for ER and PgR were compared using Pearson's chi-square (χ 2 ) test. Kappa statistics were used as a concordance measurement. Sensitivity, specificity, false negative rate, false positive rate, positive predictive value, negative predictive value, overall accuracy and the Youden index were calculated. The significance level used in all tests was 5%. 
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RESULTS
Validation by the reference laboratory
Comparison of results between reference and local laboratories
The 500 cases of invasive breast carcinoma included in the study were classified as invasive ductal carcinoma that was not otherwise specified (93.8%) and invasive lobular carcinoma (2.6%).
Micropapillary, apocrine, tubular, papillary, metaplastic and mucinous carcinomas were rarely found (3.6%), as shown in 
DISCUSSION
Brazil has a population of approximately 190 million people. 35 The incidence of breast cancer in Brazil is about 50,000 new cases per year, 36 and it is considered to be an important public health problem.
Hormone receptor status should be defined in all newly diagnosed, invasive breast carcinomas as well as in recurrences, in order to determine patient eligibility for hormone therapy, which provides substantial survival benefit for patients with hormonepositive tumors. Accurate determination of ER and PgR status is, therefore, critical for ensuring that patients receive appropriate therapy. [2] [3] [4] [5] [6] [7] [8] 30 However, discordances in hormone receptor testing using IHC have been reported in different laboratories from several countries, and these probably relate to technical issues, including delayed or inadequate fixation, non-optimized antigen retrieval and diversity of interpretation and reporting of results.
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In 2000, Rhodes et al. 10 demonstrated that there was considerable variability between laboratories (200 laboratories in 26 countries) regarding ER results, especially in relation to detection of breast cancers with low ER positivity, with a false-negative rate ranging from 30% to 60%. This variability between laboratories probably related to differences in IHC methodology, according to these authors.
In 2001, in a study that involved 105 laboratories, the same authors showed that the efficiency of the antigen retrieval step was the single most important contributory factor influencing the overall reproducibility of the hormone assays. 
